Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [<sup>18</sup>F]FDG PET/CT imaging: quantitative analysis of [<sup>18</sup>F]FDG uptake in primary tumors and metastatic lymph nodes.

Wang, DaQuan; Zhang, Xu; Liu, Hui; Qiu, Bo; Liu, SongRan; Zheng, ChaoJie; Fu, Jia; Mo, YiWen et al. · Eur J Nucl Med Mol Imaging · 2022

Where this comes from

Abstract

This study aimed to quantitatively assess [<sup>18</sup>F]FDG uptake in primary tumor (PT) and metastatic lymph node (mLN) in newly diagnosed non-small cell lung cancer (NSCLC) using the total-body [<sup>18</sup>F]FDG PET/CT and to characterize the dynamic metabolic heterogeneity of NSCLC. The 60-min dynamic total-body [<sup>18</sup>F]FDG PET/CT was performed before treatment. The PTs and mLNs were manually delineated. An unsupervised K-means classification method was used to cluster patients based on the imaging features of PTs. The metabolic features, including Patlak-Ki, Patlak-Intercept, SUV<sub>mean</sub>, metabolic tumor volume (MTV), total lesion glycolysis (TLG), and textural features, were extracted from PTs and mLNs. The targeted next-generation sequencing of tumor-associated genes was performed. The expression of Ki67, CD3, CD8, CD34, CD68, and CD163 in PTs was determined by immunohistochemistry. A total of 30 patients with stage IIIA-IV NSCLC were enrolled. Patients were divided into fast dynamic FDG metabolic group (F-DFM) and slow dynamic FDG metabolic group (S-DFM) by the unsupervised K-means classification of PTs. The F-DFM group showed significantly higher Patlak-Ki (P < 0.001) and SUV<sub>mean</sub> (P < 0.001) of PTs compared with the S-DFM group, while no significant difference was observed in Patlak-Ki and SUV<sub>mean</sub> of mLNs between the two groups. The texture analysis indicated that PTs in the S-DFM group were more heterogeneous in FDG uptake than those in the F-DFM group. Higher T cells (CD3<sup>+</sup>/CD8<sup>+</sup>) and macrophages (CD68<sup>+</sup>/CD163<sup>+</sup>) infiltration in the PTs were observed in the F-DFM group. No significant difference was observed in tumor mutational burden between the two groups. The dynamic total-body [<sup>18</sup>F]FDG PET/CT stratified NSCLC patients into the F-DFM and S-DFM groups, based on Patlak-Ki and SUV<sub>mean</sub> of PTs. PTs in the F-DFM group seemed to be more homogenous in terms of [<sup>18</sup>F]FDG uptake than those in the S-DFM group. The higher infiltrations of T cells and macrophages were observed in the F-DFM group, which suggested a potential benefit from immunotherapy.

Medical subject headings